JP2015502397A - 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 - Google Patents

部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 Download PDF

Info

Publication number
JP2015502397A
JP2015502397A JP2014548303A JP2014548303A JP2015502397A JP 2015502397 A JP2015502397 A JP 2015502397A JP 2014548303 A JP2014548303 A JP 2014548303A JP 2014548303 A JP2014548303 A JP 2014548303A JP 2015502397 A JP2015502397 A JP 2015502397A
Authority
JP
Japan
Prior art keywords
engineered
polypeptide
amino acid
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502397A5 (https=
Inventor
マーケット キンバリー
マーケット キンバリー
ベネット エリック
ベネット エリック
チスティアコヴァ リオウドミラ
チスティアコヴァ リオウドミラ
エル． トゥメイ ネイサン
エル． トゥメイ ネイサン
バイカー ジャック
バイカー ジャック
カラブロ ヴァレリー
カラブロ ヴァレリー
グラツィアーニ エドムンド
グラツィアーニ エドムンド
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2015502397A publication Critical patent/JP2015502397A/ja
Publication of JP2015502397A5 publication Critical patent/JP2015502397A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014548303A 2011-12-23 2012-12-19 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 Pending JP2015502397A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580169P 2011-12-23 2011-12-23
US61/580,169 2011-12-23
PCT/IB2012/057491 WO2013093809A1 (en) 2011-12-23 2012-12-19 Engineered antibody constant regions for site-specific conjugation and methods and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017106142A Division JP2017206512A (ja) 2011-12-23 2017-05-30 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用

Publications (2)

Publication Number Publication Date
JP2015502397A true JP2015502397A (ja) 2015-01-22
JP2015502397A5 JP2015502397A5 (https=) 2016-02-12

Family

ID=47678913

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014548303A Pending JP2015502397A (ja) 2011-12-23 2012-12-19 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2017106142A Pending JP2017206512A (ja) 2011-12-23 2017-05-30 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2018174655A Pending JP2019034942A (ja) 2011-12-23 2018-09-19 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2020181624A Active JP7165175B2 (ja) 2011-12-23 2020-10-29 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017106142A Pending JP2017206512A (ja) 2011-12-23 2017-05-30 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2018174655A Pending JP2019034942A (ja) 2011-12-23 2018-09-19 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP2020181624A Active JP7165175B2 (ja) 2011-12-23 2020-10-29 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用

Country Status (6)

Country Link
US (1) US11147852B2 (https=)
EP (2) EP3539982B1 (https=)
JP (4) JP2015502397A (https=)
CA (2) CA3111357A1 (https=)
ES (2) ES2721882T3 (https=)
WO (1) WO2013093809A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018509933A (ja) * 2015-02-16 2018-04-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
JP2018538283A (ja) * 2015-11-30 2018-12-27 ファイザー・インク 部位特異的コンジュゲーションのための抗体および抗体断片
JP2020517913A (ja) * 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2023536143A (ja) * 2020-07-29 2023-08-23 メディトックス インク． ヘテロ二量体Ｆｃ融合タンパク質、並びに関連の組成物、用途及び方法
JP2024505577A (ja) * 2021-02-03 2024-02-06 ミシク セラピューティクス， インコーポレイテッド 抗体およびその使用
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
AU2011243294C1 (en) 2010-04-21 2015-12-03 Syntarga B.V. Novel conjugates of CC-1065 analogs and bifunctional linkers
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
HK1214282A1 (zh) 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
CN104936621A (zh) 2012-11-07 2015-09-23 辉瑞公司 抗IL-13受体α2抗体和抗体-药物缀合物
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
CN105283201B (zh) 2013-03-14 2019-08-02 斯克利普斯研究所 靶向剂抗体偶联物及其用途
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
KR102453188B1 (ko) * 2013-06-24 2022-10-07 넥스이뮨, 인크. 면역요법을 위한 조성물 및 방법
KR101899306B1 (ko) * 2013-07-03 2018-10-04 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
WO2015035044A2 (en) * 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
MX375378B (es) * 2013-09-27 2025-03-06 Genentech Inc Formulaciones de anticuerpos anti-pdl1.
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
EP3057991B8 (en) 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
BR112016012538A2 (pt) 2013-12-17 2017-09-26 Novartis Ag peptídeos citotóxicos e conjugados dos mesmos
CN105899236B (zh) 2014-01-10 2019-07-26 斯索恩生物制药有限公司 表现出改进的体内抗肿瘤活性的倍癌霉素adc
HUE029672T2 (en) 2014-01-10 2017-03-28 Synthon Biopharmaceuticals Bv Duokarmicin-ADCs for use in the treatment of endometrial cancer
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
CA2940451A1 (en) * 2014-03-12 2015-09-17 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
ES2895623T3 (es) * 2014-05-22 2022-02-22 Byondis Bv Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes
KR102451080B1 (ko) 2014-06-12 2022-10-06 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. 효소적 방법을 통한 균일한 항체 약물 접합체
SG11201610620UA (en) 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CN106536540A (zh) 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US20160074527A1 (en) 2014-09-17 2016-03-17 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
ES2884844T3 (es) 2015-03-09 2021-12-13 Agensys Inc Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
US10870706B2 (en) 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
MY188430A (en) 2015-04-10 2021-12-08 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2016207091A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
EP4180455A1 (en) * 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
US10689458B2 (en) * 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
AU2016377371A1 (en) 2015-12-21 2018-08-09 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
SG11201805557SA (en) 2016-01-08 2018-07-30 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
WO2017134547A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
AU2017213886B2 (en) 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
CN107216392A (zh) * 2016-03-17 2017-09-29 华东师范大学 蟾蜍毒素衍生物的抗体药物偶联物及其制备方法和应用
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
WO2018025168A1 (en) 2016-08-03 2018-02-08 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
WO2018031258A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201903400WA (en) 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
BR112019014588A2 (pt) 2017-01-17 2020-02-18 Amgen Inc. Método de tratamento ou amenização de distúrbios metabólicos usando agonistas do receptor de glp-1 conjugados a antagonistas para receptor do peptídeo inibidor gástrico (gipr)
MX395639B (es) 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
MX2019008773A (es) 2017-01-24 2019-09-18 Pfizer Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
ES2977788T3 (es) 2017-04-20 2024-08-30 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
JP7073487B2 (ja) * 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体
WO2019018647A1 (en) 2017-07-20 2019-01-24 Pfizer Inc. ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US12150990B2 (en) 2017-11-02 2024-11-26 Nanjing Shunxin Pharmaceutical Co., Ltd. Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody
JP7506601B2 (ja) 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ，インク． 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
UY38050A (es) 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
TW202519260A (zh) 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
BR112021005472A2 (pt) 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
EP3886913A4 (en) * 2018-11-30 2023-01-11 Prism | Proteogenomics Research Institute for Systems Medicine IMPROVED TARGETED DELIVERY OF THERAPEUTICS
CN117843795A (zh) * 2019-03-11 2024-04-09 凯惠科技发展(上海)有限公司 一种含半胱氨酸的抗体、药物偶联物及其应用
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
JP7500619B2 (ja) * 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
AU2020328038B2 (en) 2019-08-13 2025-10-09 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US11802151B2 (en) * 2019-11-04 2023-10-31 Code Biotherapeutics, Inc. Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
CA3165846A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
EP4090686A4 (en) * 2020-01-17 2024-03-27 Immune Targeting Inc. PRO-ANTIBODY REDUCING OFF-TARGET TOXICITY
CN115175930A (zh) * 2020-02-05 2022-10-11 中外制药株式会社 用于产生和/或富集重组抗原结合分子的方法
EP4110404A1 (en) * 2020-02-28 2023-01-04 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
WO2022026915A2 (en) * 2020-07-31 2022-02-03 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2022056354A1 (en) * 2020-09-11 2022-03-17 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
WO2022104692A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Engineered antibody, antibody-drug conjugate, and use thereof
US20240174730A1 (en) * 2021-02-25 2024-05-30 Cidara Therapeutics, Inc. Variant fc domains and uses thereof
EP4649959A2 (en) 2021-04-14 2025-11-19 Kodiak Sciences Inc. Methods of treating an eye disorder
IL308163A (en) 2021-05-03 2024-01-01 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
CN118475372A (zh) * 2021-10-29 2024-08-09 博尔特生物治疗药物有限公司 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途
WO2024005424A1 (ko) * 2022-06-29 2024-01-04 고려대학교 산학협력단 FCγRIIA 결합 선택성이 향상된 인간 FC 변이체
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
TW202500193A (zh) * 2023-03-22 2025-01-01 美商信立泰生物醫藥公司 抗５ｔ４抗原結合結構域、抗體－藥物共軛體及彼等之使用方法
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments
WO2026055183A1 (en) 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038024A1 (en) * 2006-09-29 2008-04-03 Ucb Pharma S.A. Altered antibodies
JP2008516896A (ja) * 2004-09-23 2008-05-22 ジェネンテック・インコーポレーテッド システイン操作抗体および結合体
JP2011502126A (ja) * 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2011509675A (ja) * 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
WO2011044368A1 (en) * 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
JPH08501085A (ja) 1992-08-26 1996-02-06 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗腫瘍剤としてのサイトカインｉｐ−１０の利用
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
ATE234635T1 (de) 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
AU753157B2 (en) 1997-11-03 2002-10-10 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth
CZ20003099A3 (cs) 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
US7208668B2 (en) 2003-07-15 2007-04-24 Kabushiki Kaisha Kawai Gakki Seisakusho Keyboard device for keyboard instrument
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US8435517B2 (en) 2008-09-17 2013-05-07 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US7346003B2 (en) 2004-07-02 2008-03-18 Texas Instruments Incorporated Method of increasing noise immunity with a simulated preamble
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
DK1896071T3 (en) 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
GB0513852D0 (en) 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
WO2008020827A2 (en) 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
ATE536373T1 (de) 2005-10-21 2011-12-15 Genzyme Corp Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
JP4732277B2 (ja) * 2006-08-23 2011-07-27 トヨタ自動車株式会社 ガス分析装置及びガス分析方法
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
US20110091992A1 (en) 2007-07-10 2011-04-21 Medimmune, Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
JP5427348B2 (ja) 2007-10-12 2014-02-26 株式会社医学生物学研究所 エフェクター機能が向上した抗体
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
US8273415B2 (en) 2009-06-03 2012-09-25 Saint-Gobain Adfors Canada, Ltd. Method of forming a reinforcement sheet to reinforce a cementitious board
CA2763935A1 (en) 2009-06-04 2010-12-09 Novartis Ag Methods for identification of sites for igg conjugation
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US8926543B2 (en) 2009-10-08 2015-01-06 Otsuka Pharmaceutical Co., Ltd. Immunoactivation blood perfusion filter for the treatment of malignant tumors
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
WO2011156382A1 (en) 2010-06-07 2011-12-15 Paskonis Almantas K Vehicle liftgate striker and latch construction
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
CN104684928A (zh) 2012-08-02 2015-06-03 Jn生物科学有限责任公司 通过半胱氨酸突变和μ尾端多聚化的抗体或融合蛋白
CN104936621A (zh) 2012-11-07 2015-09-23 辉瑞公司 抗IL-13受体α2抗体和抗体-药物缀合物
KR102447350B1 (ko) 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN106459055B (zh) 2014-01-27 2019-11-01 辉瑞大药厂 双功能细胞毒类药剂
WO2015187428A1 (en) 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
US10870706B2 (en) 2015-03-20 2020-12-22 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
TWI812873B (zh) 2015-11-30 2023-08-21 美商輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段
WO2018025168A1 (en) 2016-08-03 2018-02-08 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516896A (ja) * 2004-09-23 2008-05-22 ジェネンテック・インコーポレーテッド システイン操作抗体および結合体
WO2008038024A1 (en) * 2006-09-29 2008-04-03 Ucb Pharma S.A. Altered antibodies
JP2011502126A (ja) * 2007-10-31 2011-01-20 ゼンコア インコーポレイテッド ＦｃＲｎへの変異結合を有するＦｃ変異体
JP2011509675A (ja) * 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
WO2011044368A1 (en) * 2009-10-07 2011-04-14 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 21, JPN6016046965, 2010, pages 385 - 392, ISSN: 0003453835 *
NATURE BIOTECHNOLOGY, vol. 26, no. 8, JPN6016046966, 2008, pages 925 - 932, ISSN: 0003453836 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 39, JPN6016046968, 2000, pages 30445 - 30450, ISSN: 0003453838 *
THERAPEUTIC DELIVERY, vol. 2, no. 3, JPN6016046967, March 2011 (2011-03-01), pages 397 - 416, ISSN: 0003453837 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155610B2 (en) 2014-06-28 2021-10-26 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP7439024B2 (ja) 2015-02-16 2024-02-27 ロンザ リミテッド Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
JP2018509933A (ja) * 2015-02-16 2018-04-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
US11833222B2 (en) 2015-02-16 2023-12-05 Lonza Ltd CL and/or CH1 mutated antibodies for drug conjugation
JP2021175762A (ja) * 2015-02-16 2021-11-04 ロンザ リミテッドLonza Limited Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体
JP2018538283A (ja) * 2015-11-30 2018-12-27 ファイザー・インク 部位特異的コンジュゲーションのための抗体および抗体断片
JP7414371B2 (ja) 2015-12-30 2024-01-16 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
JP2022037072A (ja) * 2015-12-30 2022-03-08 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
JP2019510734A (ja) * 2015-12-30 2019-04-18 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 抗体および抗体複合体
CN108712911A (zh) * 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
JP2020517913A (ja) * 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023536143A (ja) * 2020-07-29 2023-08-23 メディトックス インク． ヘテロ二量体Ｆｃ融合タンパク質、並びに関連の組成物、用途及び方法
JP7608592B2 (ja) 2020-07-29 2025-01-06 メディトックス インク． ヘテロ二量体Ｆｃ融合タンパク質、並びに関連の組成物、用途及び方法
JP2024505577A (ja) * 2021-02-03 2024-02-06 ミシク セラピューティクス， インコーポレイテッド 抗体およびその使用
US12331125B2 (en) 2021-02-03 2025-06-17 Mythic Therapeutics, Inc. Anti-cMet antibody-drug conjugates and uses thereof
JP7745640B2 (ja) 2021-02-03 2025-09-29 ミシク セラピューティクス， インコーポレイテッド 抗体およびその使用

Also Published As

Publication number Publication date
ES2721882T3 (es) 2019-08-06
EP2794653B1 (en) 2019-03-13
ES3027182T3 (en) 2025-06-13
JP2019034942A (ja) 2019-03-07
JP2017206512A (ja) 2017-11-24
EP3539982A3 (en) 2020-01-15
CA2859755A1 (en) 2013-06-27
WO2013093809A1 (en) 2013-06-27
US20160008485A1 (en) 2016-01-14
JP7165175B2 (ja) 2022-11-02
EP3539982C0 (en) 2025-02-19
EP2794653A1 (en) 2014-10-29
CA3111357A1 (en) 2013-06-27
JP2021019632A (ja) 2021-02-18
US11147852B2 (en) 2021-10-19
CA2859755C (en) 2021-04-20
EP3539982A2 (en) 2019-09-18
EP3539982B1 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
JP7165175B2 (ja) 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
JP7218396B2 (ja) 二重特異性抗体
CN102802661B (zh) 用于位点特异性偶联的工程改造的Fc区
JP6014596B2 (ja) 均一コンジュゲーションのための抗体足場
US20200069764A1 (en) Antibodies and antibody fragments for site-specific conjugation
KR20100058509A (ko) 다중특이적 에피토프 결합 단백질 및 이의 용도
KR20170002405A (ko) 포유동물 세포를 사용한 이종다량체 단백질의 생산
AU2015205870A1 (en) ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
HK1196090A (en) Engineered fc regions for site-specific conjugation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170821